Table 1: Definition of dyslipidemia or treatment goal of patients with CHD or equivalents on serum lipid level.

OriginationDefinition of dyslipidemia or treatment goal of Patients with CHD or equivalents on serum lipid level

ATP I 1988 [14]Ideal lipid level: mmol/L (200 mg/dL); mmol/L (130 mg/dL). Patients with HDL- (35 mg/dL) were defined unmoral. The definition of dyslipidemia was according to the level of LDL-C

ATP II 1993 [15]Treatment goal: LDL- mmol/L (100 mg/dL)

Ministry of Health of the People’s Republic of China 1993 [8]The treatment goal was not introduced

CADPS 1997 [16]Treatment goal: mmol/L (180 mg/dL);  mmol/L (150 mg/dL); LDL-  mmol/L (100 mmol /L)

ATP III 2001 [17]Treatment goal: LDL-  mmol/L (100 mg/dL)

Implication of ATP III 2004 [18]Treatment goal: LDL-  mmol/L (100 mg/dL); the optional goal: LDL-  mmol/L (70 mg/dL)

AHA/ACC Guideline 2006 [19]Treatment goal: LDL-  mmol/L (100 mmol/L), and it is seasonal for lower than 1.8 mmol/L (70 mg/dL)

CADPG 2007 [3]Treatment goal:  mmol/L (160 mg/dL) and LDL-  mmol/L (100 mg/dL) for CHD or equivalents
Treatment goal:  mmol/L (120 mg/dL); LDL-  mmol/L (80 mg/dL) for ACS or ischemic cardiovascular disease complicated with diabetes mellitus
Suitable scope of HDL-C: 1.04 mmol/L (40 mg/dL); suitable scope of TG: <1.7 mmol/L (150 mg/dL)

ESC/EAS 2011 [1]In patients at very high CV risk (established CVD, type 2 diabetes, type I diabetes with target organ damage, moderate to severe CKD or a score ), the LDL-C goal is <1.8 mmol/L (70 mg/dL) and/or 50% LDL-C reduction when target level cannot be reached (I A recommendation)